Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy-Reference-Cited by-同舟云学术

Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy

Published:2023-09 Issue:9 Volume:25 Page:986-992
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Winkelmann Michael^ORCID,Blumenberg Viktoria^ORCID,Rejeski Kai^ORCID,Quell Christina,Bücklein Veit L.^ORCID,Ingenerf Maria^ORCID,Unterrainer Marcus,Schmidt Christian,Dekorsy Franziska J.,Bartenstein Peter,Ricke Jens,von Bergwelt-Baildon Michael,Subklewe Marion,Kunz Wolfgang G.

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference30 articles.

1. Chimeric antigen receptor therapy;June;N Engl J Med,2018

2. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

3. Chimeric antigen receptor T cells in refractory B-cell lymphomas;Schuster;N Engl J Med,2017

4. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

5. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic utility of 18F-FDG PET parameters in lymphoma patients under CAR-T-cell therapy: a systematic review and meta-analysis;Frontiers in Immunology;2024-09-02

2. Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy;Annals of Hematology;2023-10-20

3. Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy;Journal for ImmunoTherapy of Cancer;2023-10

4. Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria;Cancer Imaging;2023-05-15